Which Statement is NOT True About Seborrheic Dermatitis?
The answer is D) Topical corticosteroids are contraindicated - this statement is FALSE and therefore the correct answer to this question. Topical corticosteroids are NOT contraindicated in seborrheic dermatitis; in fact, they are a standard treatment option.
Analysis of Each Statement
Statement A: Scaling and Erythema - TRUE
Seborrheic dermatitis is indeed characterized by scaling and erythema. The condition presents with "greasy yellowish scaling, itching, and secondary inflammation" 1. More specifically, it manifests as "erythematous patches and plaques with white-to-yellow greasy scale" 2.
Statement B: Distribution Pattern - TRUE
The typical distribution is accurately described. Seborrheic dermatitis "affects the ears, scalp, central face, and other sebaceous areas of the skin" 1. It "primarily affects areas with a high density of sebaceous glands, such as the scalp, face, central anterior trunk, and body folds" 3. The sternum and upper back are indeed commonly involved sebaceous-rich areas.
Statement C: Associated Conditions - TRUE
The associations with Parkinson's disease, acute illness, and HIV infection are well-established. The evidence explicitly states that "seborrheic dermatitis is more pronounced in patients with Down syndrome, HIV infection, and Parkinson's disease" 1. These associations reflect the complex interplay between neurological, immunological, and systemic factors in the disease pathogenesis 2.
Statement D: Topical Corticosteroids Contraindicated - FALSE
This is the incorrect statement. Topical corticosteroids are actually recommended for seborrheic dermatitis management. The guidelines clearly state that "Treatment includes the use of topical antifungal medications to reduce the amount of yeast present and topical anti-inflammatory medications to reduce inflammation and itch" 1. The recent expert consensus emphasizes "prioritizing combined antifungal and anti-inflammatory strategies for both acute flares and long-term maintenance" 4.
Topical anti-inflammatory agents, including corticosteroids, are explicitly mentioned as "the mainstay of treatment of mild-to-moderate seborrheic dermatitis" 3. While the duration of corticosteroid use should be monitored to avoid adverse effects, they are certainly not contraindicated.
Statement E: Chronic Inflammatory Disorder with Sebum Overproduction - TRUE
Seborrheic dermatitis is correctly described as a chronic inflammatory disorder. It is "a chronic inflammatory skin condition" 2 and "a common chronic dermatosis predominantly affecting sebum-rich areas" 5. While the exact role of sebum is complex, the condition does involve "sebaceous activity" as a predisposing factor 6, and current understanding points to alterations in "the amount or composition of sebum" as part of the pathobiology 6.
Clinical Pearls
- Treatment approach: Combine topical antifungals (to address Malassezia yeast) with topical anti-inflammatory agents (corticosteroids or calcineurin inhibitors) 3, 4
- Maintenance therapy: Long-term management strategies are important given the chronic, relapsing nature of the condition 4
- Systemic therapy: Reserved for severe or resistant cases 3
- Emerging options: Newer treatments like topical phosphodiesterase-4 inhibitors (roflumilast 0.3% foam) provide noncorticosteroid alternatives 3